Drugs.com

APRIL 30, 2025

2024, GlaxoSmithKline withdrew Flovent from the market. WEDNESDAY, April 30, 2025 More children stopped using steroid inhalers to control their asthma after a manufacturer discontinued a popular inhaler, a new study says.In The inhaler was c.

Marketing 242

Marketing Production 242

Drugs.com

OCTOBER 10, 2023

They are marketed with. MONDAY, Oct. 9, 2023 -- Flavoring added to small, cheap cigars is making these the second-most popular tobacco product among youth, a new report shows. The report comes as federal regulators prepare to bar flavored cigars.

Marketing 264

Marketing Regulations Production 264

BioPharma Drive: Drug Pricing

AUGUST 8, 2023

The Indianapolis drugmaker is now worth more than $500 billion, higher than any other pharmaceutical company, as analysts project lucrative markets for its obesity and Alzheimer's drugs.

Marketing 246

Marketing Pharmaceutical Companies Drugs Pharmaceuticals 246

Drugs.com

JULY 19, 2024

FRIDAY, July 19, 2024 -- The U.S. Food and Drug Administration on Thursday authorized the sale of the country's best-selling e-cigarette.The agency's decision only applies to several tobacco-flavored versions of the reusable product, sold as Vuse.

Marketing 264

Marketing FDA Production Drugs 264

BioPharma Drive: Drug Pricing

JUNE 18, 2025

The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market dominated by oral medicines.

FDA Approval 277

FDA Approval FDA Marketing Drugs 277

BioPharma Drive: Drug Pricing

JANUARY 17, 2024

The offering is the fifth outlined by a biotech startup this month, suggesting companies are becoming more willing to gauge investors’ appetite for new stock offerings.

Marketing 309

Marketing 309

Drugs.com

FEBRUARY 21, 2024

WEDNESDAY, Feb. 21, 2024 -- A popular asthma inhaler was discontinued on Jan. 1, and the business move has left families scrambling to find a replacement for their kids.Flovent was one of the most commonly prescribed drugs for childhood asthma, but.

Marketing 293

Marketing Drugs 293

BioPharma Drive: Drug Pricing

APRIL 25, 2025

The drug, being developed for a rare genetic disorder and currently under review in the U.S., is seen by some investors as critical to Biohaven’s future.

Marketing 265

Marketing Drugs 265

Drug Channels

NOVEMBER 15, 2024

The authors outline the challenges that manufacturers face when integrating internal and external datasets to build market access and commercialization strategies. TThey argue that unified datasets and the addition of AI-driven analytics tools can improve decision making throughout a drug’s life cycle.

Marketing 98

Marketing International Drugs 98

BioPharma Drive: Drug Pricing

JULY 22, 2024

Private biotech company acquisitions are on their fastest pace in years, a trend some in the industry say is driven by the abundance of mature, but not yet public, drug startups.

Marketing 253

Marketing Drugs 253

BioPharma Drive: Drug Pricing

SEPTEMBER 26, 2024

The withdrawal comes as trial results indicate safety concerns with the drug, Oxbryta, which was first approved in the U.S.

Trials 274

Trials Marketing Drugs 274

Drug Patent Watch

JUNE 16, 2025

A new analysis from Drug Patent Watch reveals the hidden timeline behind generic drug entry, and the market dynamics that will be reshaped in its wake. Read the full report: [link] #pharmaceuticals #patentexpiration #genericdrugs"

Marketing 67

Marketing Drugs Pharmaceuticals 67

Drug Channels

JUNE 18, 2025

Below, we share DCI’s latest analysis of the top 15 specialty pharmacies, including updated market shares and revenue estimates. DCI has identified nearly 1,900 dispensing locations with specialty pharmacy accreditation.

Specialty Pharmacies 75

Specialty Pharmacies Pharmacy Marketing Drugs 75

Drug Patent Watch

APRIL 10, 2025

The team at Drug Patent Watch has done an incredible job of breaking down the key considerations for turning scientific discoveries into market power. "Just spent the morning digging into the world of pharmaceuticals and I'm blown away by the complexities of drafting effective drug patent applications.

Science 74

Science Marketing Drugs Pharmaceuticals 74

BioPharma Drive: Drug Pricing

MARCH 24, 2025

Understanding private sector breakthroughs, acquisitions and funding is critical in a volatile market.

Marketing 152

Marketing 152

Crucial Data Solutions

JUNE 10, 2025

The Post-Market Shift: From Sites to Data Streams Phase IV trials used to mean tracking long-term outcomes by continuing to. The post Modern Post-Market Trials Will Be Driven by RWD – Is Your EDC Ready? appeared first on Crucial Data Solutions.

Trials 59

Trials Marketing Clinical Trials 59

BioPharma Drive: Drug Pricing

FEBRUARY 9, 2024

Shortly after Kyverna priced one of the sector’s largest IPOs in recent years, Maag spoke with BioPharma Dive about what it takes to go public now.

Marketing 189

Marketing 189

BioPharma Drive: Drug Pricing

OCTOBER 29, 2024

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

Vaccine 161

Vaccine Marketing 161

BioPharma Drive: Drug Pricing

APRIL 7, 2025

Study results in a rare form of obesity could help the company expand use of Imcivree, which is approved for two genetically driven forms of excess weight.

Marketing 141

Marketing Drugs 141

BioPharma Drive: Drug Pricing

APRIL 29, 2025

Deals with Hims & Hers, LifeMD and Ro following a court's dismissal of a lawsuit challenging the FDA's determination that Wegovy is no longer in shortage.

Marketing 152

Marketing FDA 152

Drugs.com

FEBRUARY 21, 2025

FRIDAY, Feb. 21, 2025 -- New York Attorney General Letitia James filed a major lawsuit yesterday, accusing 13 e-cigarette companies of illegally selling flavored vapes and targeting young kids through deceptive marketing.The 192-page complaint.

Marketing 147

Marketing 147

Drug Patent Watch

APRIL 1, 2025

Read the full market analysis on the impact of biosimilars on the generic drug industry in Europe: [link] What do you think is the most significant challenge facing the generic drug industry in Europe as it navigates the biosimilar revolution? Share your thoughts in the comments below.

Biosimilars 78

Biosimilars Marketing Drugs Government 78

BioPharma Drive: Drug Pricing

MARCH 26, 2025

Clearance of Vykat unlocks what analysts anticipate will be a lucrative market opportunity for Soleno Therapeutics.

FDA 321

FDA Marketing Drugs 321

BioPharma Drive: Drug Pricing

SEPTEMBER 12, 2024

The offerings by Bicara, Zenas and MBX give a glimpse into what industry insiders describe as a backlog of mature startups waiting for the right opportunity to test public markets.

Marketing 327

Marketing 327

BioPharma Drive: Drug Pricing

NOVEMBER 11, 2024

Negative drug results cost AbbVie billions of dollars in market value and convinced analysts that Bristol Myers had placed a better bet in buying Karuna Therapeutics.

Drugs 321

Drugs Marketing 321

Science Daily: Pharmacology News

AUGUST 16, 2024

With new medications on the market or in the works for Alzheimer's disease and other kinds of dementia, a new study suggests that getting the diagnosis needed to access these new treatments may depend on where you live.

Treatment 325

Treatment Disease Marketing 325

Science Daily: Pharmacology News

AUGUST 8, 2024

A research team has recently developed a novel artificial compound eye system that is not only more cost-effective, but demonstrates a sensitivity at least twice that of existing market products in small areas.

Production 336

Production Marketing Research 336

BioPharma Drive: Drug Pricing

JULY 3, 2024

Multibillion-dollar buyouts from Bristol Myers Squibb and Gilead could yield new drugs for brain and liver diseases, while a new cell therapy may reach market.

FDA 312

FDA Therapies Disease Marketing 312

BioPharma Drive: Drug Pricing

OCTOBER 13, 2023

Sales of Pfizer's antiviral Paxlovid and shot Comirnaty have been slower than it anticipated, while a shift to the commercial market for the antiviral has been delayed.

Production 342

Production Marketing 342

BioPharma Drive: Drug Pricing

MARCH 8, 2024

The results have led Amylyx to pause promotion of Relyvrio and potentially pull it from the market in the coming weeks, a major blow to the company and ALS patients.

Marketing 342

Marketing Drugs 342

Science Daily: Pharmacology News

AUGUST 1, 2024

What if the 'Market Economy' always existed? Archaeologists tried to answer this question by researching how much Bronze Age people used to spend to sustain their daily lives. Their results show that, starting at least 3,500 years ago, the spending habits of prehistoric Europeans were not substantially different from what they are today.

Marketing 323

Marketing Research 323

BioPharma Drive: Drug Pricing

JULY 11, 2024

Far behind companies like Novo and Eli Lilly, Pfizer hopes the version of the drug, danuglipron, that it’s chosen to advance can break into the ultra-lucrative market for weight-loss medicines.

Marketing 312

Marketing Drugs 312

BioPharma Drive: Drug Pricing

DECEMBER 4, 2024

Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, a finding that could advantage Lilly in the companies’ market competition.

Drug Trials 306

Drug Trials Trials Treatment Marketing 306

BioPharma Drive: Drug Pricing

NOVEMBER 22, 2024

The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market that investors have been skeptical BridgeBio can win.

FDA 300

FDA Marketing Drugs 300

BioPharma Drive: Drug Pricing

AUGUST 2, 2024

Adaptimmune’s Tecelra is the first TCR cell therapy to reach market and, at $727,000, is also the priciest cellular medicine for cancer in the U.S.

Therapies 300

Therapies FDA Marketing 300

BioPharma Drive: Drug Pricing

NOVEMBER 14, 2024

But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market. A key regulatory committee sided against the drug this summer.

Regulations 300

Regulations Drugs Marketing 300

Fierce BioTech

JUNE 9, 2025

Widening the Pharma Marketing Funnel with AI-Powered Engagement: Ostro's Approach to Converting Interest into Action Learn how leading pharma brands are boosting digital engagement by applying consumer-tech strategies like AI-driven personalization and intuitive UX.

Marketing 52

Marketing 52